Gujarat Themis Biosyn has informed that the Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July 03, 2026 for Pharmaceutical Business Group (India).
The above information is a part of company’s filings submitted to BSE.